Skip to content

Cart

Your cart is empty

Continue shopping
Asia’s Pharmaceutical Expansion Is Changing the Logistics Brief
Nov 3, 20265 min read

Asia’s Pharmaceutical Expansion Is Changing the Logistics Brief

Shanghai, Singapore, Tokyo and Seoul all featured in DHL’s October announcement of six new dedicated healthcare air corridors. Later that month, Merck KGaA opened a bioprocessing production centre in South Korea, adding more than €300 million of company-reported investment to its Asia-Pacific manufacturing network.

The announcements concern different parts of the pharmaceutical supply chain. DHL is expanding connections into Asian healthcare markets; Merck is bringing manufacturing inputs closer to the companies using them. Together, they show investment in both the region’s production capabilities and the infrastructure connecting it with international markets.

For pharmaceutical businesses, the practical question is what these investments make possible. Can materials be sourced closer to production? Does a dedicated healthcare corridor offer a better route into an Asian market? And how should packaging change when more of the journey takes place within controlled infrastructure?

New connections into Asian markets

On 12 October 2026, DHL Global Forwarding announced six healthcare corridors: Liège-Shanghai, Brussels-Shanghai, Brussels–Singapore, Cincinnati–Singapore, Cincinnati–Tokyo Narita and Cincinnati-Seoul Incheon.

DHL says the services combine temperature-controlled aircraft compartments, thermal blankets and validated handling processes. Most flights operate within its own network, an arrangement intended to reduce handovers and give the company greater control over shipments.

For manufacturers supplying Asian customers, the value lies in the combination of transport capacity and a defined healthcare handling process. A dedicated corridor offers something more specific to assess than a general airfreight booking, although DHL’s reliability benefits remain company claims rather than comparative results disclosed in the announcement.

The next step is a lane-level conversation. A manufacturer shipping into Seoul needs to understand which temperature range the service supports, how freight transfers between facilities and what happens if the planned connection is missed. The destination city alone does not answer those questions.

The announcement also describes connections into Asia. Companies evaluating exports from Asian manufacturing sites should establish the relevant outbound service separately, rather than assuming identical arrangements apply in reverse.

Singapore is adding infrastructure around the flight

Singapore provides a clear example of how the investment extends beyond aircraft capacity.

On 4 September 2026, Changi Airport Group and DHL announced a dedicated healthcare logistics facility at Changi Nexus One. The planned 3,047-square-metre Singapore Coldchain Hub will support 2°C to 8°C and 15°C to 25°C handling, with direct airside access and temperature monitoring. Completion is targeted for the end of 2027; this is future capacity, not an operational facility available today.

The distinction matters for supply-chain planning. A route assessment made now must use the infrastructure currently available. Longer-term distribution plans can consider the proposed facility, while allowing for its actual opening, service scope and qualification requirements.

Direct airside access is commercially relevant because it addresses the movement between aircraft and warehouse. For temperature-sensitive cargo, that transfer is part of the protection requirement, even when the flight and storage facility are both controlled.

For companies using Singapore as a regional gateway, the useful assessment therefore extends beyond the international arrival. It needs to establish how shipments will be stored, consolidated or broken down, and how protection continues when goods leave the hub for their next destination.

Manufacturing investment creates a different set of movements

Merck’s Daejeon bioprocessing centre, opened on 29 October, adds another dimension to the regional picture. The facility will supply materials used in biologics development and manufacturing, including cell culture media, process liquids and sterile sampling products.

This is not a finished-medicine factory or a cold-chain distribution centre. Its significance is the addition of a regional source for materials used by biopharmaceutical manufacturers. Merck describes the investment as part of its strategy to supply customers from within their region.

For a manufacturer considering that source, the logistics brief begins with the individual material. Temperature requirements, shipment frequency and delivery arrangements need to be established product by product; participation in biologics manufacturing does not make every input a refrigerated shipment.

Where sourcing does become more regional, the transport pattern may change. A long international movement could be replaced by a shorter cross-border service, or deliveries could become smaller and more frequent. Those are possibilities to evaluate with suppliers, rather than benefits to assume from the facility announcement.

The packaging assessment follows that decision. It needs to reflect the actual dispatch location, order size and journey to the receiving plant.

Better infrastructure can change the packaging requirement

The relationship between logistics investment and thermal packaging is not simply that more pharmaceutical activity requires more insulation.

In its Singapore investment announcement, DHL explicitly describes the planned infrastructure as a way to reduce exposure and the need for supplementary temperature-control measures and packaging. That is a design objective, not a demonstrated outcome across every customer lane, but it presents an important commercial challenge for packaging suppliers.

If a product can remain within suitable controlled conditions for more of its journey, the packaging requirement may change. The task is to establish where protection is still needed and for how long.

A shipment moving through a dedicated Singapore healthcare facility may have a different exposure profile from one continuing through a general freight warehouse. A delivery to a metropolitan manufacturing plant should be assessed separately from onward distribution to regional customers. Neither route should inherit its packaging specification solely from the international flight.

This makes cooperation between the manufacturer, logistics provider and packaging supplier more valuable. Each holds part of the information needed to define the complete journey.

Regional expansion needs local execution

For businesses expanding pharmaceutical operations in Asia, packaging availability belongs in the planning discussion alongside freight capacity.

A tested configuration needs to be obtainable at the dispatch site, with the required coolant conditioning and clear packing instructions. If a new source or route introduces a different shipper size, the origin facility must have room to store and prepare it. Supply arrangements also need to accommodate routine demand and disruption.

The commercial comparison should include those operating requirements. A lower packaging price may be offset by freight volume, conditioning costs or additional assembly time. Conversely, better-controlled transport may allow a more efficient solution where the supporting evidence justifies it.

DHL’s corridors, Singapore’s planned hub and Merck’s Daejeon investment each expand a different part of the regional network. Their value to an individual pharmaceutical business will depend on how those capabilities connect with its products and customers.

The immediate opportunity is to assess those connections in detail. Which service is available now? Which materials can be sourced regionally? Where does temperature protection pass from infrastructure to packaging? Answering those questions turns a regional investment story into a workable distribution plan.

Information reviewed on 3 November 2026. Announced facilities and company-reported benefits are distinguished from operational capabilities.